angiography, PCI, FFRangio

Editor's Note: This is Part Two of a three-part series highlighting several of the presentations from the American College of Cardiology’s Annual Scientific Session (ACC.26) that took place in March in New Orleans, Louisiana.

 

April 28, 2026 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon 3.0 software. This marks a major step forward as it brings coronary imaging and AI-automated insights together in one system to support better patient outcomes and help reduce risks.

April 26, 2026 — New results from the multicenter catheter ablation versus anti-arrhythmic drugs for Ventricular Tachycardia (CAAD-VT) trial show that catheter ablation may reduce ventricular tachycardia (VT) events in patients with ischemic and non-ischemic cardiomyopathy. Researchers presented these findings as a late-breaking clinical trial at Heart Rhythm 2026 in Chicago.  

April 24, 2026 — University of Texas Health Science Center at Houston (UTHealth Houston) has established the Department of Cardiology at McGovern Medical School, marking a significant milestone in the university’s efforts to advance cardiovascular care, research and education across the region.

April 27, 2026 — Banner Health recently announced it has reached a major milestone completing more than 50 total artificial heart implantation procedures. This achievement solidifies the nonprofit health system’s position as the global leader in total artificial heart technology, with expertise that extends beyond patient care to consulting with medical centers and device manufacturers around the world on patient selection, surgery and management of total artificial hearts. 

April 24, 2026 — Johnson & Johnson recently announced the initiation of the PERSIGMA randomized controlled trial (RCT), one of the first randomized studies evaluating competitive pulsed field ablation (PFA) technologies. In this rapidly advancing field, there is an increasing need for head-to-head data that provides insights on how different technologies influence outcomes in practice. PERSIGMA RCT reflects a deliberate step forward to generate clear, comparative evidence and bring greater rigor to how PFA technologies are evaluated.

April 24, 2026 – Findings from the North American COVID-19 Myocardial Infarction (NACMI) registry demonstrate significantly higher one-year mortality rates in patients with COVID-19 and ST-elevation myocardial infarction (STEMI) compared to patients with STEMI alone. This registry is the first study to describe long-term outcomes in patients with STEMI and COVID-19.

April 26, 2026 – New results from the pivotal multicenter trial FULCRUM-VT show that ultra-low temperature ablation (ULTA) may offer a promising new treatment option for patients with ventricular tachycardia (VT) and structural heart disease. Researchers presented these findings as a late-breaking clinical trial at Heart Rhythm 2026 in Chicago.

April 24, 2026 – A novel detection algorithm spotted moderate-to-severe aortic stenosis (AS) with a sensitivity of 90.5% of all patients and 100% of African American patients.

April 24, 2026 — A new analysis from the NOAH – AFNET 6 trial shows that artificial intelligence (AI) can help unlock data from pacemakers to better understand stroke risk in patients with device-detected atrial fibrillation (AF). The study found that patients who spent more time in AF did not have a higher risk of stroke or other cardiovascular events than those who spent less time in AF. Researchers presented these findings today as a late-breaking clinical trial at Heart Rhythm 2026.  

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now